Read the latest insights on emerging CAR T therapies. This personalized treatment has shown promising results in certain types of cancers by harnessing the power of the immune system to fight disease.
A real-world investigation provides the rationale for enrolling more diverse populations in future clinical trials evaluating idecabtagene vicleucel (ide-cel).
At oral session OA-F about plasma cell disorders, updated data from the CARTITUDE-2 trial of cilta-cel CAR-T in multiple myeloma were presented.